If you have Crohn’s disease and your gastroenterologist has mentioned moving to biologic infusion therapy, you’re probably comparing names that sound mysterious — Remicade, Entyvio, Stelara — without much context for what makes them different. Here’s a clear comparison of the three most commonly prescribed Crohn’s biologics, written for patients trying to make sense of their options.
The big picture: why biologics for Crohn’s?
Crohn’s disease is driven by an immune system that mistakenly attacks the lining of your digestive tract. Older medications like corticosteroids work by suppressing the entire immune system — effective but with substantial side effects over time. Biologics are designed to be more precise: they target specific proteins or cells involved in the inflammatory process, leaving the rest of your immune system mostly intact.
The three biologics below all do this, but they target different points in the inflammatory cascade. Which one is right for you depends on your disease pattern, what you’ve tried before, and how your gastroenterologist reads your case.
Remicade (infliximab) — the TNF-alpha inhibitor
How it works: Blocks tumor necrosis factor alpha (TNF), one of the master switches of inflammation in Crohn’s. By neutralizing TNF, Remicade reduces inflammation, prevents tissue damage, and allows the gut lining to heal.
Schedule: Loading doses at weeks 0, 2, and 6, then maintenance every 6 to 8 weeks. Each infusion takes 2 to 3 hours.
Best for: Patients with moderate to severe Crohn’s, particularly with fistulizing disease (where the inflammation creates abnormal connections between the gut and other tissues). Remicade is the most studied biologic for fistulizing Crohn’s and remains a first-line choice for many gastroenterologists.
Watch-outs: Because TNF is involved in fighting infections, Remicade slightly increases your risk of infections. You’ll be screened for tuberculosis and hepatitis B before starting, and you should report fevers or unusual infections promptly. Some patients develop antibodies against the drug over time, which can cause it to lose effectiveness — this is one reason your doctor may add a low-dose immunomodulator like methotrexate.
Biosimilars available: Inflectra, Renflexis, Avsola — all FDA-approved as equivalent to Remicade and typically less expensive.
Entyvio (vedolizumab) — the gut-selective biologic
How it works: Blocks alpha-4 beta-7 integrin, a protein that allows immune cells to migrate specifically to the gut. By preventing this homing process, Entyvio reduces inflammation precisely in the digestive tract while leaving immune cells elsewhere in the body relatively unaffected.
Schedule: Loading doses at weeks 0, 2, and 6, then maintenance every 8 weeks. Each infusion takes only about 30 minutes — one of the shorter biologic infusions available.
Best for: Patients who want a biologic with a particularly favorable safety profile, especially those with infection concerns or older patients. Because Entyvio works locally in the gut rather than system-wide, the infection risk is meaningfully lower than with TNF inhibitors. It’s also a good option for patients who haven’t responded to TNF inhibitors.
Watch-outs: Entyvio tends to work more slowly than Remicade — many patients don’t see full benefit until 3 to 6 months in. Patience is part of the protocol. It’s also generally less effective than TNF inhibitors for patients with significant fistulizing disease or for extra-intestinal manifestations like joint inflammation, since it works specifically in the gut.
Biosimilars available: Not yet, though they’re expected.
Stelara (ustekinumab) — the IL-12/23 inhibitor
How it works: Blocks two related signaling proteins (interleukin-12 and interleukin-23) that drive chronic inflammation in autoimmune conditions. Stelara interrupts a different inflammatory pathway than the TNF or integrin pathways.
Schedule: A single weight-based IV loading infusion (about 1 hour), then maintenance is typically a subcutaneous injection every 8 weeks at home. Some patients continue with IV maintenance.
Best for: Patients who have lost response to TNF inhibitors, or those for whom TNF inhibitors aren’t a good fit. Stelara has shown durable response and remission rates in patients who’ve failed other biologics, making it a valuable second- or third-line option. Because maintenance is typically self-administered at home after the initial IV loading, it can be more convenient long-term than infusion-based regimens.
Watch-outs: Like other biologics, Stelara modestly increases infection risk. It can take 8 weeks or longer to see initial response. Cost can be substantial without good insurance coverage, though manufacturer assistance programs are available.
Biosimilars available: Selarsdi, Wezlana, Pyzchiva — recently FDA-approved.
How do gastroenterologists choose?
The honest answer is that there’s no single algorithm. Your doctor weighs several factors:
- Disease severity and pattern. Fistulizing Crohn’s often points toward Remicade. Inflammatory disease without fistulas opens the field.
- Prior treatments. If you’ve never tried a biologic, all three are reasonable. If you’ve failed a TNF inhibitor, Entyvio or Stelara become more attractive.
- Infection risk. Older patients, immunocompromised patients, or those with recurrent infections may do better on Entyvio.
- Lifestyle. Stelara’s eventual self-injection maintenance schedule is convenient for some patients. Others prefer the structure of regular infusion appointments.
- Insurance and cost. Coverage and copays can vary substantially across these three. We help verify benefits before your first infusion.
- Extra-intestinal symptoms. If you have joint pain, skin involvement, or eye inflammation along with Crohn’s, TNF inhibitors or Stelara may help both gut and non-gut symptoms.
Switching biologics
It’s common to need more than one biologic over the course of Crohn’s disease. Some patients respond beautifully to the first medication and stay on it for years. Others lose response over time and need to switch. This isn’t failure — it’s a normal part of managing a chronic, evolving disease. The fact that we have three different mechanisms (TNF, integrin, IL-12/23) means there’s usually another option if one stops working.
What about other options?
Beyond these three, newer biologics including Skyrizi (risankizumab, an IL-23 inhibitor) and Omvoh (mirikizumab) have been approved more recently for Crohn’s. Smaller molecules like Rinvoq (a JAK inhibitor) are oral options. The biologic landscape for IBD continues to expand — ask your gastroenterologist about the full menu of options for your specific case.
At Arbor
We administer all three biologics discussed here, plus their biosimilars. Our infusion team has extensive experience with IBD patients, and we coordinate directly with your gastroenterologist throughout your treatment course.
Ready to learn more? Read the dedicated pages on Remicade, Entyvio, or Stelara, or contact us with questions.